Personalizing COPD Therapy According to Recent Clinical Trial Evidence

Introduction

Therapeutic Recommendations

Therapeutic Recommendations in Groups B and D

Bronchodilators in Stable COPD

ICS in Stable COPD

COPD Potential AEs of ICS Treatment

Diabetes Onset on ICS

FLAME: IND/GLY vs SFC for COPD Exacerbations in High-Risk Population

FLAME: Primary Endpoint Noninferiority and Superiority for IND/GLY vs SFC

FLAME: Effect of IND/GLY on Time to First Exacerbation Compared With SFC

Triple Studies Comparisons

Triple Studies Comparisons (cont)

TRIBUTE LABA/LAMA/ICS vs LABA/LAMA

TRIBUTE Rate of Moderate and Severe Exacerbations

TRIBUTE Main AEs and Serious AEs

IMPACT LABA/LAMA/ICS vs LABA/ICS + LABA/LAMA

Evolution of Exacerbations

IMPACT Effect on Pneumonia

SUNSET Trial Design

Primary Endpoint: Change From Baseline in Postdose Trough FEV1 (Noninferiority Analysis)

SUNSET Rate of COPD Exacerbations During the 26-Week Treatment Period

Exacerbation Rate Analysis and Blood Eosinophil Levels

WISDOM: ICS Withdrawal Did Not Increase the Exacerbations in Patients With Severe COPD

WISDOM Post-Hoc Analysis ICS Withdrawal and Exacerbation Risk

DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations

DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations (cont)

GOLD Recommendations in the Group D

Airway Obstruction and Lung Hyperinflation in COPD Are Linked to an Impaired Left Ventricular Diastolic Filling

Interaction of Heart and Lung in COPD Hyperinflation vs Diastolic Filling

CLAIM Study Design

CLAIM Study Results

Lung Deflation With Indacaterol/Glycopyrronium Improves Pulmonary Microvascular Blood Flow

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)